Clinical Audit of Non-Selective Beta Blockers Titration in the Management of
Swaleh Kitabu Pazi, Ally Hamisi Mwanga, Tuzo A Lyuu, Masolwa Ng’wanasayi, John Rwegasha, Ewaldo Vitus Komba, Igembe Nkandala
Background: Portal hypertension – a major complication of chronic liver disease – is associated with multiple complications that
include ascites, varices, and hepatic encephalopathy; these complications can lead to substantial morbidity and mortality. Randomized
control trials have demonstrated the efficacy of nonselective beta blockers (NSBB) for preventing primary and secondary gastroesophageal variceal bleeding. These drugs should be titrated to target the resting heart rate of 55–60 beats per minute and the systolic
blood pressure should not decrease <90 mm Hg. The objective of this study was to perform an audit of the titration of nonselective
beta blockers in patients with portal hypertension at the national referral hospital
